Yanlong Li

Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms

Alfonso Quintás‐Cardama, Kris Vaddi, Phillip Liu et al. · Blood · 2010 · 827 citations

Medicine, Hematology, Pharmacology +11

Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity

Xiangdong Liu, Niu Shin, Holly K. Koblish et al. · Blood · 2010 · 559 citations · Full text

Medicine, Immunology, Oncology +14

Selective Inhibition of JAK1 and JAK2 Is Efficacious in Rodent Models of Arthritis: Preclinical Characterization of INCB028050

Jordan S. Fridman, Peggy Scherle, Robert J. Collins et al. · The Journal of Immunology · 2010 · 463 citations · Full text

Medicine, Immunology, Pharmacology +17

Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer

Bin-Bing Zhou, Michael Peyton, Biao He et al. · Cancer Cell · 2006 · 375 citations · Full text

Medicine, Molecular Biology, Oncology +11

INCB24360 (Epacadostat), a Highly Potent and Selective Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitor for Immuno-oncology

Eddy W. Yue, Richard Sparks, Padmaja Polam et al. · ACS Medicinal Chemistry Letters · 2017 · 296 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +8